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Background: Exposure to urinary catheters is considered the most important risk factor for healthcare-associated
urinary tract infection (UTI) and is associated with significant morbidity and substantial extra-costs. In this study, we
assessed the impact of urinary catheterisation (UC) on symptomatic healthcare-associated UTI among hospitalized
patients.
Methods: A nationwide period prevalence survey of healthcare-associated infections was conducted during 1 May
to 30 June 2004 in 49 Swiss hospitals and included 8169 adult patients (4313 female; 52.8%) hospitalised in medical,
surgical, intermediate, and intensive care wards. Additional data were collected on exposure to UC to investigate
factors associated with UTI among hospitalised adult patients exposed and non-exposed to UC.
Results: 1917 (23.5%) patients were exposed to UC within the week prior to survey day; 126 (126/8169; 1.5%)
developed UTI. Exposure to UC preceded UTI only in 73 cases (58%). By multivariate logistic regression analysis, UTI
was independently associated with exposure to UC (odds ratio [OR], 3.9 [95% CI, 2.6-5.9]), female gender (OR, 2.1
[95% CI, 1.4-3.1]), an American Society of Anesthesiologists’ score > 2 points (OR, 3.2 [95% CI, 1.1-9.4], and prolonged
hospital stay >20 days (OR, 1.9 [95% CI, 1.4-3.2]. Further analysis showed that the only significant factor for UTI with
exposure to UC use was prolonged hospital stay >40 days (OR, 2.9 [95% CI, 1.3-6.1], while female gender only
showed a tendency (OR, 1.6 [95% CI, 1.0-2.7]. In the absence of exposure to UC, the only significant risk factor for
UTI was female gender (OR, 3.3 [95% CI, 1.7-6.5]).
Conclusions: Exposure to UC was the most important risk factor for symptomatic healthcare-associated UTI, but
only concerned about half of all patients with UTI. Further investigation is warranted to improve overall infection
control strategies for UTI.
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Indwelling urinary catheters (UC) are an integral part of
medicine today [1,2], and as many as one-quarter of all
patients require their placement during hospital stay [3].
Exposure to UC is currently considered the most important
risk factor for healthcare-associated urinary tract infection
(UTI) and is associated with significant morbidity [3-5] and
substantial extra-costs [6,7]. The literature suggests that the
rate of UTI acquisition is 5% per day of UC use [3]. Despite
the harm potential and the existence of educational
programmes to prevent unnecessary catheterisation, UC
continues to be frequently used or maintained without clear
indications [3,4,8].
In Switzerland, nationwide period prevalence surveys
of healthcare-associated infections have been regularly
conducted for the past 15 years and provide a unique
opportunity to gain insight into their epidemiology
[9-12]. During the 2004 survey, we collected additional
data on exposure to UC and evaluated factors associated
with UTI among hospitalised adult patients exposed and
non-exposed to UC.
Methods
Setting and study organization
Five nationwide period prevalence surveys of healthcare-
associated infections have been conducted since 1996 in
Switzerland in over 100 acute care hospitals [9-12]. These
were coordinated by SwissNOSO, an independent panel of
experts in infectious diseases and hospital epidemiology
representing all Swiss university-affiliated hospitals.
Hospital participation was voluntary. Observers were
infection control practitioners who attended at least
three one-day training sessions during which detailed
documentation was provided in their native language,
including the study protocol, standardised case report form,
written definitions for all study variables, practical exercises,
and code lists [9]. The prevalence study was scheduled to
assess all healthcare-associated infections. All nurses and
physicians performing the study were trained to distinguish
between community and healthcare-associated infections;
the latter was defined as symptomatic infection occurring
after 48 h of hospital admission. Infection control practi-
tioners from centres with and without experience in preva-
lence studies were grouped as study teams and supervised
by an infection control physician at each centre [9,12].
Study population and methodology
All patients hospitalised for at least 24 h during the survey
conducted in May-June 2004 were assessed using a standar-
dised case report form. Dermatological, ophthalmological,
paediatric, and psychiatric wards were excluded, as well as
long-term care sectors, defined as wards with a median
hospital stay >30 days. In each hospital, one or several
teams of two trained observers with experience in infectioncontrol reviewed simultaneously all medical and nursing
charts and evaluated patients for the presence of
healthcare-associated infections and potential risk factors
within a fixed time window, defined as the survey day plus
the six previous days. Observers rated their interpretation
of chart data on a six-point Likert scale (1 = strongly dis-
agree; 6 = strongly agree). All results were checked by the
data manager and physicians in the study centre for plausi-
bility and completeness, and corrected if necessary. The fol-
lowing variables were assessed for each patient: gender; age;
immune suppression; hemiplegia; surgery; antibiotic use;
hospital size; ward type; and length of hospital stay at time
of survey. All non-surgical wards, e.g., neurology, rheuma-
tology, were classified as medical wards. Acuity and severity
of the underlying illness were assessed by the American As-
sociation of Anesthesiologists’ (ASA) score [13], McCabe
and Jackson classification [14], Charlson comorbidity index
[15], and nursing workload on survey day [16].
Definitions
Definitions for healthcare-associated infections were
adapted from those of the United States Centers for Disease
Control and Prevention (CDC) [17] as previously described
[9,11]. UTI was the primary outcome and defined as an
infection occurring after 48 h of hospitalisation, unless the
patient was transferred from another hospital and cumula-
tive hospital stay reached 48 h. Clinical (dysuria, pollaki-
suria, fever or shivering), laboratory (urine sedimentation
profiles, urinary tract cultures), medical and/or radiological
data (ultrasound or computed tomography scans) were
required for the confirmation of infection in the absence of
other signs or explications. Only the first episode of symp-
tomatic UTI for each patient was recorded. Asymptomatic
urinary tract colonization (CDC code, UTI-ASB) was not
considered as UTI [9,10]. Previous exposure to UC was the
secondary outcome. Exposure to UC, intensive care, and
antibiotics were only considered when they lasted for at
least 24 h. A condom collection system was not considered
as UC. Duration of exposure to UC was censored at 30 days.
Surgery was defined as any procedure performed in the
operating room within 30 days prior to survey day.
Statistical analysis
The primary outcome was the occurrence of symptomatic
UTI. First, we compared patients with and without UTI by
using Chi-2 or Fisher’s exact tests for categorical variables.
We used Student’s t-test or the non-parametric
Mann–Whitney test to compare continuous variables.
To take into account hospital clustering, we used a logistic
regression model with a random effect at the hospital level
(cluster effect) to assess the independent association
between the main predictor (previous exposure to UC) and
UTI after adjustment for the main confounders (gender,
age, severity scores [McCabe, ASA], length of hospital stay,
Table 1 Patient characteristics according to the presence of
healthcare-associated urinary tract infection (UTI) (n = 8169),
Swiss-NOSO Nationwide Prevalence Study, 2004
UTI No UTI P value
(n = 126) (n = 8043)
Urinary catheter exposure (%) <0.001
Yes 73 (57.9) 1912 (23.8)
No 53 (42.1) 6131 (76.2)
Gender, female (%) 85 (67.5) 4228 (52.6) 0.001
Mean age (±SD) 71.8 (15.6) 62.4 (19.0) <0.001
Age groups (%) <0.001
<40 years 7 (5.7) 1395 (17.9)
41-70 years 37 (30.3) 3208 (41.2)
> = 71 years 78 (63.9) 3184 (40.9)
Hospital size 0.09
<200 acute care beds 23 (18.3) 1994 (24.8)
200-500 beds 40 (31.8) 2748 (34.2)
> = 501 beds 63 (50.0) 3301 (41.0)
Mean length of stay (±SD) 20.5(22.2) 11.4 (41.0) <0.001*
Length of stay <0.001
<20 days 89 (70.6) 6990 (86.9)
21-40 days 22 (17.5) 677 (8.4)
> = 41 days 15 (11.9) 374 (4.7)
Recent stay in intensive care (%) 34 (27.0) 1030 (12.8) <0.001
Hospitalisation ward (%) 0.003*
Medical ward 45 (35.7) 3192 (39.7)
Surgical ward 50 (39.7) 3219 (40.0)
Gynaecology/obstetrics 5 (4.0) 778 (9.7)
Intensive care unit 7 (5.6) 285 (3.5)
Medico-surgical 19 (15.1) 569 (7.1)
Recent surgery (%) 61 (48.4) 3292 (40.9) 0.09
Mean ASA score (±SD) 2.81 (0.67) 2.33 (0.89) <0.001*
ASA (%) <0.001*
1 pt 4 (3.2) 1587 (19.8)
2-3 pts 109 (87.2) 5802 (72.3)
4-5 pts 12 (9.6) 634 (7.9)
McCabe/Jackson (%) 0.01*
Non fatal 82 (65.1) 6143 (76.4)
Fatal within 5 years 36 (28.6) 1455 (18.1)
Fatal within 6 months 8 (6.4) 445 (5.5)
Mean nursing workload (±SD) 204.0 (161.4) 168.3 (162.8) 0.008*
Mean Charlson index (±SD) 1.8 (2.1) 1.2 (1.8) <0.001*
Charlson group (%) 0.02
0-3 pts 106 (84.1) 7267 (90.4)
> = 4 pts 20 (15.9) 776 (9.7)
Co-morbidities (%)
Diabetes mellitus 19 (15.1) 1074 (13.4) 0.57
Table 1 Patient characteristics according to the presence of
healthcare-associated urinary tract infection (UTI) (n = 8169),
Swiss-NOSO Nationwide Prevalence Study, 2004
(Continued)
Immune suppression° 26 (20.6) 1047 (13.0) 0.01
Hemiplegia 24 (19.1) 777 (9.7) <0.001
Dementia 9 (7.1) 290 (3.6) 0.04
ASA, American Society of Anesthesiologists; (%) = proportion of all surveyed
patients according to number of the variable of interest among the study
population; SD = standard deviation; °autoimmune disease, transplantation,
hepatopathy, nephropathy, neoplasia.
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assess the independent association between the secondary
outcome (use of UC) and various risk factors. For both
models, we used a backward stepwise procedure by selec-
ting all variables associated with a p <0.20 at univariate and
kept in the model all those significantly associated with the
outcome (p <0.05). As we suspected that the pathophysi-
ology of UTI differed according to gender and those
exposed/not exposed to UC, we tested for an interaction
between both variables and provided a stratified model on
urinary catheter exposure/gender. We tested also for all
interactions that were biologically plausible. Finally, we
assessed the independent association between prior expo-
sure to UC (secondary outcome) and the main confounders
(gender, age, severity scores [McCabe, ASA], hospital length
of stay, co-morbidities). The significance level was 0.05
(two-tailed). Statistical testing was performed, using SAS
statistical software, version 9.2 (SAS Institute).
Results
A total of 8169 patients from 49 hospitals participated in
the survey, representing a nationwide estimate of at least
30% of all hospitalised patients; 4313 (52.8%) were female
[12]. Among these, 1917 (23.5%) were exposed to UC with
an overall median duration of use of 4 days (interquartile
range, 2–9 days). Of 126 patients overall who developed
UTI (1.5%; 85 female; median age, 77 years), 73 (58%) had
been exposed to UC within the week preceding UTI onset,
while 53 (42%) had no exposure. Sixty-two percent of all
case report forms for UTI patients were maximally rated
(6/6 points on the Likert scale) by observers and a further
25% with almost complete agreement (5/6 points). Females
were at higher risk for UTI (odds ratio [OR], 2.1 [95% con-
fidence interval (CI), 1.4-3.1]). Four UTI episodes were
classified as upper UTI or abscesses, and six were bacter-
aemic. We identified a total of 14 different causative
pathogens, of which the most frequent in descending
order were Escherichia coli, Proteus spp, Klebsiella spp,
Enterobacter spp, and Enterococcus spp. On average, UTI
was diagnosed 16 days after admission (range, 2 to 124 d).
Patient population characteristics stratified according to
the occurrence of UTI are shown in Table 1. The 38
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colonization were excluded according to our study
protocol.
Multivariate adjustment
Overall UTI
By multivariate logistic regression analysis with a random
effect at the hospital level, independent factors associated
with higher odds for UTI were prior exposure to UC
(odds ratio, OR, 3.9 [95% CI, 2.6-5.9]), female gender
(OR, 2.1 [95% CI, 1.4-3.1]), ASA score of > 2 points
(OR, 3.2 [95% CI, 1.1-9.4], and prolonged hospital
stay > 20 days (OR, 1.9 [95% CI, 1.4-3.2]. When
female gender and prior exposure were combined with
UC as one risk factor, the likelihood of UTI increased by
10.4-fold compared to the combination of male gender
and no prior exposure to UC. Women not exposed to UC
had a 3.4-fold risk of UTI compared to men not exposed
to UC. The likelihood of UTI increased independently
with age, ASA group, and the length of hospital stay, after
adjustment on the main other confounders (Tables 2 & 3).
UTI with and without prior UC exposure
In the model assessing the likelihood of UTI stratified
on prior exposure to UC (Table 2), the only factor sig-
nificantly associated was a prolonged hospital stay >
40 days, while female gender showed only a tendency for
association. In the model stratified on no prior exposure
to UC, female gender, hemiplegia, and a recent stay
in intensive care all increased significantly the odds
for UTI.
UTI stratified by gender
In the model assessing the likelihood of UTI stratified by
gender (Table 3), prior exposure to UC was significantly
associated with UTI for both, whereas the length of
hospital stay was significantly associated with UTI for
women, but not for men.
Exposure to UC
We investigated the variables associated with the use of
UC after stratification by gender. There were no diffe-
rences between genders according to exposure to UC. The
following factors were independently associated with a
higher odds for the use of UC: age >70 years; recent surgi-
cal intervention; ASA score > 4 points; Charlson index > 4
points; high McCabe classification; recent stay in intensive
care; and hemiplegia.
Discussion
In this large study of patients hospitalised in Swiss acute
care facilities, 25% were exposed to UC and 1.5% developed
symptomatic UTI. Congruent with our results and other
national and regional prevalence studies, a European reportestimated a prevalence of nosocomial UTI of 1.65%
(Table 4). Our findings mirror reports revealing a preva-
lence of UC use of 20.3% in emergency departments [8],
32% to 36% in acute care wards [5], and similar rates in
most surveys conducted elsewhere (Table 4). The median
duration of exposure to UC was also congruent with
the literature, i.e., 2–4 days [18-41].
By contrast, we are not able to compare healthcare-
associated UTI prevalence with prevalence encountered
in the community. Scientific data on the incidence or
prevalence of UTI in the Swiss general population are
non-existent, while the literature provides only data in
predefined populations, such as elderly men or diabetic
patients. Moreover, different survey studies define UTI
differently, e.g., by excluding or including asymptomatic
colonization. However, according to rough data, the
overall life-long incidence of UTI could be around 2-4%
for young males [42], 6.3% for older Scandinavian males
[43], and up to 20% for females. Among Saudi diabetic
males, the prevalence might be as high as 7%, whereas
asymptomatic urinary tract colonization might be as
high as 41% in diabetic women [44].
We found a significant association between UTI and
UC use. However, the relation between prior exposure
to UC and subsequent UTI was much less systematic
than expected, and UC use preceded UTI in only 58% of
cases. This does not appear to be unique to our study.
In a European study reviewing 4.4 million admissions
in 1999, 37.2% of all UTI episodes did not reveal
prior exposure to UC [4]. A proportion of 41% UTI
without prior exposure to UC has been similarly
evidenced in Italian hospitals [31], while Jespen et al.
found 56.7% of patients with healthcare-associated
UTI attributed to prior UC use [19]. These reports
did not further explore the relative low frequency of
UC use prior to UTI.
In our study population, the low rate of UTI may re-
flect the low UC utilization rates. This is not surprising.
One explanation might be recent surgery and/or a short
ICU stay as these patients are often exposed to UC and
acquire UTI more frequently than those hospitalised on
medical wards. According to survey definitions, UC use
was only recorded when it lasted > 24 h, but some
patients undergoing surgery could have been exposed to
UC for a shorter time, at least during surgery or ICU
stay. Although it cannot be excluded that short duration
catheterisation might predispose to subsequent UTI, this
is unlikely given the low UTI incidence of only 2% [45]
to 2.5% [46] at 24 h of UC use. Moreover, at least in the
largest institution involved in the current study, this
assumption would not be true [47]. Since 2001, UC
during surgery is restricted to patients with a foreseen
duration of more than 5 h or for arthroplasty surgery if
the patient meets one of the following conditions:
Table 2 Multivariate logistic regression models clustered on hospitals presenting independent factors associated with
urinary tract infection stratified on prior exposure to urinary catheter, Swiss-NOSO Nationwide Prevalence Study, 2004
Variables Prior exposure to urinary catheter No prior exposure to urinary catheter
(n = 1917) (n = 5957)
Odds ratio 95% CI P value OR 95% CI P value
Age groups (%) 0.62 0.03*
<40 years 1.00 - - 1.00 - -
41-70 years 1.77 0.51-6.10 0.36 1.03 0.31-3.45 0.96
> = 71 years 1.84 0.54-6.26 0.33 2.53 0.81-7.94 0.11
Recent surgical intervention 0.75 0.59
No 1.00 - 1.00 -
Yes 0.92 0.54-1.56 0.84 0.44-1.59
ASA score (%) 0.09* 0.39
1 pt 1.00 - - 1.00 - -
2-3 pts 7.21 0.96-54.35 0.06 1.99 0.54-7.28 0.30
4-5 pts 4.52 0.51-39.74 0.17 1.11 0.18-6.78 0.91
Charlson group 0.55 0.76
0-3 pts 1.00 - 1.00 -
> = 4 pts 1.30 0.55-3.08 0.85 0.30-2.40
Length of stay 0.01* 0.09*
<20 days 1.00 - - 1.00 - -
21-40 days 1.88 0.92-3.85 0.08 2.01 0.95-4.22 0.07
> = 41 days 2.87 1.34-6.11 0.006 2.12 0.84-5.35 0.11
Recent stay in intensive care 0.99 0.05*
No 1.00 - 1.00 -
Yes 1.00 0.58-1.73 2.30 1.01-5.20
McCabe/Jackson (%) 0.95 0.18
Non fatal 1.00 - - 1.00 - -
Fatal within 5 years 0.98 0.54-1.77 0.95 1.71 0.88-3.31 0.11
Fatal within 6 months 1.15 0.45-2.93 0.76 0.50 0.06-3.87 0.50
Gender 0.06* 0.001*
Male 1.00 - 1.00 -
Female 1.61 0.98-2.65 3.27 1.65-6.48
Hemiplegia 0.78 0.03*
No 1.00 - 1.00 -
Yes 1.10 0.55-2.20 2.10 1.07-4.11
Immune suppression° 0.67 0.45
No 1.00 - 1.00 -
Yes 1.18 0.54-2.58 1.42 0.57-3.51
*Independent variables significantly (or slightly significantly) associated with urinary tract infection.
ASA = American Society of Anesthesiologists; autoimmune disease, transplantation, hepatopathy, nephropathy, neoplasia.
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obesity or urinary incontinence [43,48]. Thus, only 15.7%
of all orthopaedic surgery is performed with a UC in
place. For postanaesthesia care, only 4.7% of all patients
required bladder catheterisation without permanent
insertion of a UC [46].Another population prone to intermittent catheterisa-
tion are patients with neurogenic bladders who were not
identified as such in our study protocol [49,50]. Of note,
our study involved acute care settings with the voluntary
exclusion of long-term care facilities or homes where
most patients with neurogenic bladders are usually
Table 3 Multivariate logistic regression models clustered on hospitals presenting independent factors associated with
urinary tract infection stratified on gender, Swiss-NOSO Nationwide Prevalence Study, 2004
Variables Male (n = 3703) Female (n = 4171)
Odds ratio 95% CI P value Odds ratio 95% CI P value
Age groups (%) 0.01* 0.10*
<70 years 1.00 - 1.00 - -
> = 71 years 2.57 1.24-5.31 1.51 0.93-2.45
Recent surgical intervention 0.78 0.43
No 1.00 - 1.00 -
Yes 1.11 0.55-2.21 0.82 0.49-1.35
ASA score (%) 0.30 0.47
<4 pts 1.00 - 1.00 - -
4-5 pts 0.52 0.15-1.81 0.73 0.31-1.73
Charlson group 0.50 0.89
0-3 pts 1.00 - 1.00 -
> = 4 pts 1.44 0.50-4.11 0.94 0.39-2.28
Length of stay 0.57 <0.001*
<20 days 1.00 - - 1.00 - -
21-40 days 0.86 0.26-2.92 0.81 2.75 1.52-4.96 0.001
> = 41 days 1.75 0.59-5.17 0.31 2.89 1.41-5.92 0.004
Recent stay in intensive care 0.59 0.04*
No 1.00 - 1.00 -
Yes 0.79 0.35-1.81 1.83 1.03-3.24
McCabe classification (%) 0.84 0.14*
Non fatal 1.00 - - 1.00 - -
Fatal within 5 years 0.81 0.36-1.82 0.61 1.70 0.99-2.91 0.05
Fatal within 6 months 1.11 0.31-4.04 0.87 0.98 0.32-3.00 0.98
Prior exposure to urinary catheter <0.001* <0.001*
No 1.00 - 1.00 -
Yes 6.77 3.20-14.35 3.04 1.83-5.04
Hemiplegia 0.08* 0.34
No 1.00 - 1.00 -
Yes 2.04 0.93-4.46 1.36 0.73-2.54
Immune suppression° 0.39 0.57
No 1.00 - 1.00 -
Yes 1.55 0.57-4.18 1.24 0.58-2.65
*Independent variables significantly (or slightly significantly) associated with urinary tract infection.
ASA American Society of Anesthesiologists; autoimmune disease, transplantation, hepatopathy, nephropathy, neoplasia.
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acute care settings should be low. We consider that we
have avoided a major bias by including paraplegic patients
in the study population. Finally, the exact risk of sympto-
matic UTI after one single intermittent catheterisation is
unknown. Most of the literature on intermittent cathete-
risation concerns individuals with repeated catheterisation
due to neurologic problems [49,50]. Among these patients
with intermittent self-catheterisation during several years
or months, the cumulative risk of UTI is reported to beas high as 50% according to several surveys [50].
However, these patients cannot be compared with indivi-
duals with normal bladders who are only undergoing one
single intermittent catheterisation for anaesthesiological
or surgical reasons.
UTI can complicate urological interventions and be
technically classified as surgical site infection. In a litera-
ture review, Slade reported approximately 19% UTI after
urological surgery [48]. We are unable to provide infor-
mation on the proportion of “official urological patients”
Table 4 Prevalence of urinary catheter use and/or symptomatic healthcare-associated urinary tract infection: reports in
the peer-reviewed literature (January 1980-December 2012)
Author/s Population Methodology Catheter use Infection Remarks
Jepsen et al.
[19] 1982
40 hospitals in eight
countries, n = 3899
Point prevalence 10.1% men,
11.8% women
6.5% Conducted in 1980
Moro et al.
[20] 1985
130 hospitals,
n = 34,577
Point prevalence 9.4% 2.1% National prevalence survey in Italy, 1983
Mertens et al.
[21] 1987
106 hospitals, n = 8723 Point prevalence 15.7% 4.4% National prevalence survey in Belgium 1984 70%
surgery. Definition nosocomial: > 3rd day
Srámova et al.
[22] 1988
23 hospitals, n = 12,260 Point prevalence 1.5% Prevalence survey in Czechoslovakia, 1984
Emmerson et al.
[23] 1996
157 centres, n = 37,111 Survey - 2.4% Prevalence survey in UK and Ireland, 1994
Gastmeier et al.
[24] 1997
72 hospitals, n = 14,966 Point prevalence 1.1% National prevalence survey in Germany, 1994
Scheel et al.
[25] 1999
All acute care hospitals,
n = 12,755
Point prevalence - 2.2% National prevalence survey in Norway, 1997
Vaqué et al.
[26] 1999
n = 51,674 in 1997 Point prevalence - 2.1% National prevalence surveys in Spain, 1990-1997
French Prevalence
Group [27] 2000
830 hospitals,
n = 236,334
Point prevalence 9.6% 1.6% National prevalence survey in France, 1996,
including psychiatric and long-term care wards
Eriksen et al.
[2] 2002
Acute care hospitals,
n = 11,500-12,500
Point prevalence - 1.7-2.0% National prevalence surveys in Norway,2002 and
2003
Gikas et al.
[28] 2002
n = 3925 Point prevalence 8.6% 2.1% Survey in 14 Greek hospitals, 1999
Lizioli et al.
[29] 2003
Public hospitals,
n = 18,667
Point prevalence - 1.6% Prevalence survey in Lombardy, 2000
Klavs et al.
[30] 2003
Acute care, n = 6695 Point prevalence - 1.2% National prevalence survey in Slovenia, 2001
Nicastri et al.
[31] 2003
15 hospitals in Italy,
n = 2165
Point prevalence 22.4% 1.7% All participating hospitals have > 400 beds
Wald et al. [5] 2005 Surgery, n = 111,330 523
Medicare hospitals
Retrospective
cohort study
32% at
discharge day
- Patients at discharge after hip replacement
Tammelin [32] 2005 31 hospitals, n = 6369 16.5% 1.65% Acute hospitals and long-term care facilities in
Sweden, 2002
Gravel et al.
[33] 2007
n = 5750 Point prevalence 22% 3.4% National prevalence survey in Canada, 2002
Hopmans et al.
[34] 2007
2 tertiary Dutch
hospitals, n = 2661
Point prevalence
twice a year
- 2.3%
(1.2%-3.4%)
2001-2004. Obstetric wards excluded
Kevens et al.
[35] 2007
445 US hospitals,
n = 33,726,611
Throughout the
year 2002
- 1.3% Estimations for the USA
Pelizzer et al.
[36] 2008
21 Italian hospitals,
n = 6352
Period prevalence 25.2% 2.2% Prevalence study in Veneto region, Italy 2003
van den Broek et al.
[37] 2011
10 hospitals, n = 16,495 Period prevalence 20.2% 2.6% Netherlands, acute care hospitals
Cairns et al.
[38] 2011
45 acute care hospitals,
n = 11,090
Point prevalence 20.3% 2.0% Scotland 2006, exclusion of obstetric patients
Cotter et al.
[39] 2012
69 long-term care
facilities, n = 4,170
Point prevalence 5.6% 1.5% Long-term care facilities in Ireland, June 2010
Askarian et al.
[40] 2012
8 university hospitals,
n = 3450
Point prevalence 23.1% 1.4% University hospitals in Shiraz, Iran
Health Protection
Agency [41] 2012
103 healthcare facilities,
n = 52,443
Point prevalence 18.8% 1.1% English national point prevalence survey
preliminary data
Present article Acute care hospitals,
n = 8169
Period prevalence
Cluster-adapted
24% 1.5% National prevalence survey in Switzerland, 2004
* Only reports including at least 2000 patients admitted to acute care facilities are included.
Uçkay et al. Antimicrobial Resistance and Infection Control 2013, 2:5 Page 7 of 10
http://www.aricjournal.com/content/2/1/5
Uçkay et al. Antimicrobial Resistance and Infection Control 2013, 2:5 Page 8 of 10
http://www.aricjournal.com/content/2/1/5among all those undergoing surgery, because many Swiss
surgical wards are mixed, especially in smaller hospitals, are
mixed and care for urology and non-urology patients at the
same time. Similarly, the same surgeons may often perform
urologic and other surgical interventions during the same
day. However, it is unlikely that these urologic patients
represent a large group and that freshly-operated urological
patients would have been exposed to UC for more than
24 h. Specialized, urology-only, surgical wards did not exist
in Switzerland at the time of the study and urology patients
constitute a maximum of 10% of all surgical patients in
many university centres. As summarised in Table 4, few
national prevalence studies further stratify or report
surgical specialties in detail. In the studies by Emmerson
et al. [23] and Sramova et al. [22], the proportion of
patients hospitalised on urological wards was only 3.9%
and 2.4%, respectively.
Our survey has several limitations. i) The study design
was not targeted towards delineating the origin of UTI.
The causal inference between exposure to UC and UTI
seems logical, but is not proven sensu strictu. ii) Despite
the large number of patients included, only 126 acquired
UTI. Although positive in terms of infection control, these
small numbers are associated with reduced statistical
power that is recognized in the wide confidence intervals.
iii) Results are limited to acute care sectors. Many patients
exposed to UC in high-income countries live in nursing
homes or other long-term care facilities where the preva-
lence is higher and UTI is one of the most frequent infec-
tions [1,10]. iv) Data related to antibiotic administration
or urine acidification are lacking. This could be important
as patients treated for other infections might be protected
from UTI with antimicrobials covering Gram-negative
rods, while antibiotic administration prior to hospital ad-
mission might equally have diminished the bacterial bur-
den in the genitourinary system. To the best of our
knowledge, no prevalence study has explored this theoret-
ical relationship. Of note, in our study, symptomatic UTI
occurred on average two weeks after hospital admission,
but we ignore if patients already had asymptomatic uri-
nary tract colonization before hospital admission. v) So
far, only prevalence studies and personal clinical experi-
ence report a high proportion of UTI without prior expo-
sure to UC. There are no prospective cohort studies or
randomized trials to confirm this ubiquitous finding. We
currently ignore if the ability to track the catheter as a risk
factor for nosocomial UTI might be limited when using
prevalence studies. vi) Our study protocol did not target
differences in the clinical presentation between UTI with
and without prior UC use. This may be a bias as the pre-
sence of UC may influence physicians in the work-up of
fever, i.e., they might order urine cultures more often in
patients with UC. This theoretical bias is likely to shift the
proportion of UTI towards UC use.In conclusion, exposure to UC is the most important risk
factor for healthcare-associated UTI according to preva-
lence studies, but only for a proportion of all patients ─ at
best two-thirds. This finding appears to be shared by other
local or national prevalence studies. In our study, the
separate analysis for UTI in the absence of prior UC use
revealed only female gender [48], hemiplegia [5], and
prolonged hospital stay as significant risk factors. The
cumulative impact of other less inalienable risk factors
should not be underestimated. Further research needs to
place an emphasis on innovative strategies to address the
specific issues of UTI in the absence of exposure to UC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The national prevalence study was designed by all authors. The study was
primarily coordinated by HS and IU with support from all authors, including
identifying patients and collecting data on cases. IU, HS and AG managed
the data and performed the initial analysis of cases. IU, AG, and DP drafted
the manuscript. All authors interpreted the results and revised the
manuscript.
Financial support
This study was supported by the Swiss Federal Office for Public Health and
unrestricted educational grants from Astra Zeneca, Bayer (Switzerland) AG,
BBraun Medical AG, Beiersdorf AG, Ecolab GmBH, Mundipharma AG, and
Schülke + Mayr AG.
Acknowledgments
We are indebted to Rosemary Sudan for editorial assistance, Nadia Colaizzi
for help in data processing and study organisation, and François Eggimann
for information technology support. We thank Pierre-Alain Raeber for help
and Stephan Harbarth for critical reading of the manuscript.
Parts of the study were presented at the 50th Interscience Conference on
Antimicrobial Agents and Chemotherapy Congress in Boston, USA, on 15
September 2010 (abstract #3192).
Author details
1Infection Control Programme and WHO Collaborating Centre on Patient
Safety, University of Geneva Hospitals and Faculty of Medicine, 4 Rue
Gabrielle Perret-Gentil, 1211, Geneva 14, Switzerland. 2Orthopaedic Surgery
Department, University of Geneva Hospitals and Faculty of Medicine, Geneva,
Switzerland. 3Department of Infectious Diseases, University of Geneva
Hospitals and Faculty of Medicine, Geneva, Switzerland. 4Division of
Infectious Diseases, University Hospital of Zurich, Zurich, Switzerland.
5Department of Infectious Diseases, University Hospital Bern, Bern,
Switzerland. 6Department of Infectious Diseases, Central Institute of the Valais
Hospitals, Sion, Switzerland. 7Department of Hospital Preventive Medicine,
Centre Hospitalier Universitaire Vaudois and University of Lausanne,
Lausanne, Switzerland. 8Department of Infectious Diseases, Ospedale Civico,
Lugano, Switzerland. 9Division of Infectious Diseases, University of Basel
Hospitals, Basel, Switzerland. 10Swiss Federal Office of Public Health, Bern,
Switzerland. 11Current addresses: Department of Infectious Diseases and
Hospital Hygiene, University of Zurich, Zurich, Switzerland. 12Current
addresses: Hirslanden Clinics, Zurich, Switzerland. 13Current addresses: Public
Health Service for the Canton of Vaud, Lausanne, Switzerland.
Received: 9 October 2012 Accepted: 14 January 2013
Published: 7 February 2013
References
1. Nicolle LE: Urinary tract infection in long-term-care facility residents. Clin
Infect Dis 2000, 31:757–761.
2. Eriksen HM, Iversen BG, Aavitsland P: Prevalence of nosocomial infections
in hospitals in Norway, 2002 and 2003. J Hosp Infect 2005, 60:40–45.
Uçkay et al. Antimicrobial Resistance and Infection Control 2013, 2:5 Page 9 of 10
http://www.aricjournal.com/content/2/1/53. Maki DG, Tambyah PA: Engineering out the risk for infection with urinary
catheters. Emerg Infect Dis 2001, 7:342–347.
4. Bouza E, San Juan R, Muñoz P, Voss A, Kluytmans J: Co-operative Group of
the European Study Group on Nosocomial Infections II: A European
perspective on nosocomial urinary tract infections I. Clin Microbiol Infect
2001, 7:532–542.
5. Wald H, Epstein A, Kramer A: Extended use of indwelling urinary catheters
in postoperative hip fracture patients. Med Care 2005, 43:1009–1017.
6. Foxman B: Epidemiology of urinary tract infections: incidence, morbidity,
and economic costs. Dis Mon 2003, 49:53–70.
7. Tambyah PA, Knasinski V, Maki DG: The direct costs of nosocomial
catheter-associated urinary tract infection in the era of managed care.
Infect Control Hosp Epidemiol 2002, 23:27–31.
8. Gardam MA, Amihod B, Orenstein P, Consolacion N, Miller MA:
Overutilization of indwelling urinary catheters and the development of
nosocomial urinary tract infections. Clin Perform Qual Health Care 1998,
6:99–102.
9. Pittet D, Harbarth S, Ruef C, Francioli P, Sudre P, Pétignat C, Trampuz A,
Widmer A: Prevalence and risk factors for nosocomial infections in four
university hospitals in Switzerland. Infect Control Hosp Epidemiol 1999,
20:37–42.
10. Sax H, Hugonnet S, Harbarth S, Herrault P, Pittet D: Variation in nosocomial
infection prevalence according to patient care setting: a hospital-wide
survey. J Hosp Infect 2001, 48:27–32.
11. Sax H, Swiss-NOSO: Nationwide surveillance of nosocomial infections in
Switzerland–methods and results of the Swiss Nosocomial Infection
Prevalence Studies (SNIP) in 1999 and 2002. Ther Umsch 2004,
61:197–203.
12. Sax H, Pittet D, Swiss-NOSO Network: Interhospital differences in
nosocomial infection rates: importance of case-mix adjustment. Arch
Intern Med 2002, 162:2437–2442.
13. Owens WD, Felts JA, Spitznagel EL Jr: ASA physical status classifications: a
study of consistency of ratings. Anesthesiology 1978, 49:239–243.
14. McCabe WR, Jackson GG: Gram negative bacteremia I: etiology and
ecology. Arch Intern Med 1962, 110:847–855.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987, 40:373–383.
16. Lambert P, Major L, Saint-Onge E, Saulnier D, Tilquin C, Vanderstraeten G:
L'intégration de la planification des soins et de la mesure de la charge
de travail au service des démarches scientifiques du soignant et du
gestionnaire: la méthode PRN. In Les systèmes de mesure de la charge de
travail en soins infirmiers. Edited by Thibault C. Montréal, Canada: Association
des Hôpitaux du Québec; 1990:189–194.
17. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for
nosocomial infections, 1988. Am J Infect Control 1988, 16:128–140.
18. Warren JW: Catheter-associated urinary tract infections. Int J Antimicrob
Agents 2001, 17:299–303.
19. Jepsen OB, Larsen SO, Dankert J, Daschner F, Grönroos P, Meers PD,
Nyström B, Sander J: Urinary-tract infection and bacteraemia in
hospitalized medical patients - a European multicentre prevalence
survey on nosocomial infection. J Hosp Infect 1982, 3:241–252.
20. Moro ML, Stazi MA, Marasca G, Greco D, Zampieri A: National prevalence
survey of hospital-acquired infections in Italy, 1983. J Hosp Infect 1986,
8:72–85.
21. Mertens R, Kegels G, Stroobant A, Reybrouck G, Lamotte JM, Potvliege C,
Van Casteren V, Lauwers S, Verschraegen S, Wauters G, et al: The national
prevalence survey of nosocomial infections in Belgium, 1984. J Hosp
Infect 1987, 9:219–229.
22. Srámova H, Bartonova A, Bolek S, Krecmerova M, Subertova V: National
prevalence survey of hospital-acquired infections in Czechoslovakia.
J Hosp Infect 1988, 11:328–334.
23. Emmerson AM, Enstone JE, Griffin M, Kelsey MC, Smyth ET: The Second
National Prevalence Survey of infection in hospitals-overview of the
results. J Hosp Infect 1996, 32:175–190.
24. Gastmeier P, Kampf G, Wischnewski N, Schumacher M, Daschner F, Rüden
H: Importance of the surveillance method: national prevalence studies
on nosocomial infections and the limits of comparison. Infect Control
Hosp Epidemiol 1999, 20:124–127.
25. Scheel O, Stormark M: National prevalence survey on hospital infections
in Norway. J Hosp Infect 1999, 41:331–335.26. Vaqué J, Rossello J, Arribas JL: Prevalence of nosocomial infections in
Spain: EPINE study 1990–1997. J Hosp Infect 1999, 43:105–111.
27. The French Prevalence Group: Prevalence of nosocomial infections in
France: results of the nationwide survey in 1996. J Hosp Infect 2000,
46:186–193.
28. Gikas A, Pediaditis J, Papadakis JA, Starakis J, Levidiotou S, Nikolaides P,
Kioumis G, Maltezos E, Lazanas M, Anevlavis E, Roubelaki M, Tselentis Y,
Greek Infection Control Network: Prevalence study of hospital-acquired
infections in 14 Greek hospitals: planning from the local to the national
surveillance level. J Hosp Infect 2002, 50:269–275.
29. Lizioli A, Privitera G, Alliata E, Antonietta Banfi EM, Boselli L, Panceri ML,
Perna MC, Porretta AD, Santini MG, Carreri V: Prevalence of nosocomial
infections in Italy: result from the Lombardy survey in 2000. J Hosp Infect
2003, 54:141–148.
30. Klavs I, Bufon Luznik T, Skerl M, Grgic-Vitek M, Lejko Zupanc T, Dolinsek M,
Prodan V, Vegnuti M, Kraigher A, Arnez Z: Slovenian Hospital-Acquired
Infections Survey Group: Prevalence of and risk factors for hospital-
acquired infections in Slovenia - results of the first national survey, 2001.
J Hosp Infect 2003, 54:149–157.
31. Nicastri E, Petrosillo N, Martini L, Larosa M, Gesu GP, Ippolito G: Prevalence
of nosocomial infections in 15 Italian hospitals: first point prevalence
study for the INF-NOS project. Infection 2003, 31:10–15.
32. Tammelin A: Urinary catheters and antibiotic treatment, Guidelines
adherence could be better. Lakartidningen 2005,
102:378–381.
33. Gravel D, Taylor G, Ofner M, Johnston L, Loeb M, Roth VR, Stegenga J, Bryce
E: Canadian Nosocomial Infection Surveillance Program, Matlow A: Point
prevalence survey for healthcare-associated infections within Canadian
adult acute-care hospitals. J Hosp Infect 2007, 66:243–248.
34. Hopmans TE, Blok HE, Troelstra A, Bonten MJ: Prevalence of hospital-
acquired infections during successive surveillance surveys conducted at
a university hospital in the Netherlands. Infect Control Hosp Epidemiol
2007, 28:459–465.
35. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA,
Cardo DM: Estimating health care-associated infections and deaths in U.
S. hospitals, 2002. Public Health Rep 2007, 122:160–166.
36. Pellizzer G, Mantoan P, Timillero L, Allegranzi B, Fedeli U, Schievano E,
Benedetti P, Saia M, Sax H, Spolaore P: Prevalence and risk factors for
nosocomial infections in hospitals of the Veneto region, north-eastern
Italy. Infection 2008, 36:112–119.
37. van den Broek PJ, Wille JC, van Benthem BH, Perenboom RJ, van den Akker-
van Marle ME, Niël-Weise BS: Urethral catheters: can we reduce use? BMC
Urol 2011, 11:10.
38. Cairns S, Reilly J, Stewart S, Tolson D, Godwin J, Knight P: The prevalence of
health care-associated infection in older people in acute care hospitals.
Infect Control Hosp Epidemiol 2011, 32:763–767.
39. Cotter M, Donlon S, Roche F, Byrne H, Fitzpatrick F: Healthcare-associated
infection in Irish long-term care facilities: results from the First National
Prevalence Study. J Hosp Infect 2012, 80:212–216.
40. Askarian M, Yadollahi M, Assadian O: Point prevalence and risk factors of
hospital acquired infections in a cluster of university-affiliated hospitals
in Shiraz Iran. J Infect Public Health 2012, 5:169–176.
41. Hopkins S, Shaw K, Simpson L: English national point prevalence survey on
healthcare-associated infections and antimicrobial use. London, UK: Health
ProtectionAgency; 2011. http://www.hpa.org.uk/webc/HPAwebFile/
HPAweb_C/1317134304594.
42. Kyrklund K, Taskinen S, Rintala RJ, Pakarinen MP: Lower urinary tract
symptoms from childhood to adulthood: A population bases study of
594 Finnish individuals 4 to 26 years old. J Urol 2012,
188:588–593.
43. Malmsten UGH, Milsom I, Molander U, Norlen LJ: Urinary incontinence and
lower urinary tract symptoms: an epidemiological study of men aged 45
to 99 years. J Urol 1997, 158:1733–1737.
44. Al-Rubeaan KA, Moharrem O, Al-Naqeb D, Hassan A, Rafiullah MRM:
Prevalence of urinary tract infection and risk factors among Saudi
patients with diabetes. World J Urol 2012, doi:10.10077s00345-012-0934-x.
45. Garibaldi RA, Mooney BR, Epstein BJ, Britt MR: An evaluation of daily
bacteriologic monitoring to identify preventable episodes of catheter-
associated urinary tract infection. Infect Control 1982, 3:466–70.
46. Vieira FA: Nursing actions to prevent urinary tract infection associated
with long-standing bladder catheter. Einstein 2009, 7:372–375.
Uçkay et al. Antimicrobial Resistance and Infection Control 2013, 2:5 Page 10 of 10
http://www.aricjournal.com/content/2/1/547. Stéphan F, Sax H, Wachsmuth M, Hoffmeyer P, Clergue F, Pittet D:
Reduction of urinary tract infection and antibiotic use after surgery: a
controlled, prospective, before-after intervention study. Clin Infect Dis
2006, 42:1544–1551.
48. Slade N: Postoperative urinary tract infections in urology and
gynaecology: a review. J R Soc Med 1980, 3:739–743.
49. Newman DK, Willson MM: Review of intermittent catheterization and
current best practices. Urologic Nurs 2011, 31:12–28.
50. Wyndaele JJ: Complications of intermittent catheterization: their
prevention and treatment. Spinal Cord 2002, 40:536–541.
doi:10.1186/2047-2994-2-5
Cite this article as: Uçkay et al.: High proportion of healthcare-
associated urinary tract infection in the absence of prior exposure to
urinary catheter: a cross-sectional study. Antimicrobial Resistance and
Infection Control 2013 2:5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
